Researchers analyzed data from nearly 5,000 patients with advanced or metastatic renal cell carcinoma (RCC). They compared a first-line treatment combining immune checkpoint inhibitors with anti-angiogenic therapy against the standard drug sunitinib. The study found that this combination significantly improved progression-free survival and overall survival for many patients.
The results were particularly strong for patients identified as having intermediate or poor risk of disease progression. While both treatments showed improvements in response rates, certain types of drugs within the anti-angiogenic category performed better than others. Specifically, tyrosine kinase inhibitors (TKIs) showed a balanced profile between effectiveness and safety compared to other options.
Patients on the combination therapy experienced fewer issues with fatigue and blood-related side effects. However, some patients faced risks like high blood pressure or liver issues. Because this is a meta-analysis of existing trials, it provides a broad look at current trends but does not replace individual medical advice. Patients should talk to their doctors about which specific drug combination fits their unique health profile.
